Phibro Animal Health (NASDAQ:PAHC) Sets New 52-Week High – Still a Buy?

Phibro Animal Health Co. (NASDAQ:PAHC) reached a new 52-week high during trading on Monday . The company traded as high as $25.11 and last traded at $24.84, with a volume of 105273 shares. The stock had previously closed at $23.85.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on PAHC shares. StockNews.com raised Phibro Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. JPMorgan Chase & Co. initiated coverage on shares of Phibro Animal Health in a report on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 target price for the company. Barclays raised their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a research report on Tuesday. Finally, Bank of America increased their target price on Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research note on Friday, August 30th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Phibro Animal Health presently has a consensus rating of “Hold” and a consensus target price of $16.50.

Phibro Animal Health Trading Up 0.8 %

The company has a debt-to-equity ratio of 1.81, a current ratio of 3.23 and a quick ratio of 1.69. The company has a market cap of $1.02 billion, a P/E ratio of 58.77, a P/E/G ratio of 0.66 and a beta of 0.51. The stock’s 50-day moving average is $22.57 and its two-hundred day moving average is $19.61.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, August 28th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.07. The firm had revenue of $273.16 million for the quarter, compared to the consensus estimate of $262.44 million. Phibro Animal Health had a return on equity of 21.59% and a net margin of 1.67%. As a group, equities research analysts predict that Phibro Animal Health Co. will post 1.59 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 18th. Stockholders of record on Wednesday, November 27th will be paid a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 1.90%. The ex-dividend date of this dividend is Wednesday, November 27th. Phibro Animal Health’s dividend payout ratio (DPR) is presently 111.63%.

Insider Activity at Phibro Animal Health

In other Phibro Animal Health news, Director E Thomas Corcoran purchased 5,000 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were acquired at an average cost of $20.02 per share, for a total transaction of $100,100.00. Following the completion of the transaction, the director now owns 25,000 shares of the company’s stock, valued at approximately $500,500. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 50.07% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PAHC. BNP Paribas Financial Markets raised its stake in Phibro Animal Health by 3.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 24,336 shares of the company’s stock worth $548,000 after acquiring an additional 729 shares during the period. Illinois Municipal Retirement Fund boosted its holdings in Phibro Animal Health by 7.2% in the 1st quarter. Illinois Municipal Retirement Fund now owns 11,430 shares of the company’s stock worth $148,000 after buying an additional 765 shares during the period. CWM LLC increased its stake in Phibro Animal Health by 89.8% in the 2nd quarter. CWM LLC now owns 2,188 shares of the company’s stock worth $37,000 after buying an additional 1,035 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Phibro Animal Health by 7.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,393 shares of the company’s stock valued at $200,000 after acquiring an additional 1,063 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Phibro Animal Health by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock valued at $88,000 after acquiring an additional 1,522 shares in the last quarter. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.